The purpose of the study is to determine whether the investigational drug improves symptoms compared with the control. Participants are randomly assigned to receive either the medication or the placebo, and neither the participants nor the study staff know which is given (double‑blind). The drug is administered by a small injection under the skin (subcutaneous) on a regular schedule over several weeks, with follow‑up visits to check health and record daily bowel habits.

During the study, participants keep a simple diary of stool frequency, consistency, and pain, and they attend periodic clinic visits for safety checks, such as brief physical examinations and basic laboratory tests. The overall study period lasts about four months, after which the collected information is used to assess the medication’s effect on the condition.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The main aim is to determine whether Brenipatide improves symptoms compared with placebo. Participants are assigned by chance to receive either the study drug or the placebo, and the trial is conducted in a double‑blind manner so that neither the participants nor the study staff know which treatment is administered. After a short screening period, injections are given regularly for several weeks, and participants attend clinic visits to report how they feel and to have safety checks.

Throughout the 16‑week period, the study records how many weeks each participant experiences a meaningful reduction in pain and stool difficulty, and it monitors any side effects. The collected information will help decide if the medicine is both effective and safe for people with this type of irritable bowel syndrome.

Participants will receive the assigned sedation during their colonoscopy and will be asked to complete a short questionnaire after the procedure to report how satisfied they felt. The study will also record how much medication was used, how long the procedure and recovery lasted, and any side effects or problems that occur. After the colonoscopy, participants will be monitored until they are fully awake and able to go home, and the overall success of completing the procedure will be noted.

Participants in the study will receive BI 3032950 initially through an intravenous (IV) method, which means the medication is delivered directly into a vein. After this induction phase, the treatment will continue with subcutaneous (SC) injections, where the medication is injected under the skin. The study will monitor patients over a period of time to see if they achieve clinical remission, which means a significant reduction or disappearance of symptoms, by Week 12. The study will also look at other outcomes, such as improvements seen during an endoscopy, a procedure that uses a camera to view the inside of the colon.

Throughout the study, researchers will keep track of any side effects or adverse events that may occur. The trial is designed to last up to 104 weeks, allowing for a comprehensive assessment of the treatment’s long-term effects. This study aims to provide valuable insights into whether BI 3032950 can be a beneficial treatment option for those suffering from ulcerative colitis.

The purpose of the study is to identify potential pathways in the body that lead to fibrosis in patients treated with filgotinib and to monitor these changes using FAPi-PET/CT imaging. Participants in the study will receive the treatment and undergo imaging scans to observe any changes in their condition. The study will last for several months, with participants being monitored at different stages to assess the effects of the treatment and the progression of fibrosis.

Throughout the study, researchers will analyze changes in gene and protein expression in the participants’ tissues to better understand how the treatment affects the body. This information will help in identifying specific pathways that may be involved in the development of fibrosis in ulcerative colitis. The findings from this study could provide valuable insights into new ways to manage and treat this condition in the future.

Patients will have a short “window‑of‑opportunity” period during which a small tissue sample (biopsy) is taken before the first infusion and another after the initial dose to look at immune biomarkers, which are signals that indicate how the immune system is reacting. After this phase, regular infusions continue, and doctors perform routine scans and blood tests to monitor the disease. Outcomes such as how long the cancer stays stable without growing (progression-free survival), how many patients see their tumors shrink (overall response rate), and the presence of tumor DNA fragments in the blood (ctDNA) are recorded. Additional laboratory analyses may examine genetic markers like HLA, immune‑activating proteins such as IFN-γ, the presence of immune cells marked by CD8, and the level of a protein called PD-L1 using a staining technique known as IHC. Safety is also closely watched through regular health checks and reporting of any side effects.

The aim of the trial is to find out how well REC-4881 works and how safe it is for people with this condition. Participants will take the study medication or placebo for several months, with regular visits to have blood tests that look at the drug’s pharmacokinetics—how the body absorbs and clears the medicine—and to check for any side effects. Doctors will also perform examinations of the colon to see how the number and size of polyps, known as polyp burden, change over time.

The purpose of the study is to find out if letting patients control their own sedation with remimazolam is safer and leads to higher satisfaction than when the doctor controls the sedation using either remimazolam or midazolam. Participants will be randomly assigned to one of the three groups, receive the assigned medication through an injection, and either manage the dose themselves using a simple device or have the dose given by the physician. The study follows each person through the colonoscopy, monitors for any moderate or severe side effects (known as adverse events), records how quickly they can leave the clinic (discharge), and asks about their overall experience to measure satisfaction.

The purpose is to determine whether allowing patients to choose their treatment reduces feelings of regret about that choice after twelve months. Participants are randomly placed into either the choice group or the surgery‑only group, receive the assigned treatment, and are followed for about a year with regular check‑ups.

During follow‑up, patients answer questions about any regret regarding the initial treatment, report any return of symptoms, and complete a questionnaire about overall quality of life. This information is used to compare the outcomes of the two treatment strategies.

The main goal of the trial is to find out whether LY4268989 can bring more participants into clinical remission—periods when symptoms are absent or very mild—than the placebo during the first 10 weeks and to see if the benefit continues through a longer, 52‑week maintenance phase for those who respond early. Participants will start by taking the study tablets daily for about ten weeks (the induction phase). If they show improvement, they may continue the same treatment for up to a year (the maintenance phase), with regular visits to check how they are doing.

During the study, doctors will use a scoring system called the Modified Mayo Score to decide whether a person has reached remission; this score looks at stool frequency, bleeding, endoscopic findings, and overall health. “Induction” refers to the initial treatment period aimed at quickly reducing inflammation, while “maintenance” means the ongoing treatment intended to keep the disease under control. Participants will have routine check‑ups, blood tests, and questionnaires to monitor safety and how well the medication works.

Participants are randomly assigned to receive either the lower or the standard dose of the albumin infusion at the time of the fluid‑removal procedure and are then followed for up to one year. During this period, they will have regular clinic visits where blood tests and simple questionnaires are used to check for any new health issues, such as infections of the abdominal fluid (spontaneous bacterial peritonitis), kidney problems caused by liver disease (hepatorenal syndrome – acute kidney injury), bleeding from enlarged veins in the esophagus (variceal bleeding), or changes in brain function due to liver failure (hepatic encephalopathy). The study also records overall well‑being and any hospital visits, but no technical details of the measurements are provided.

During the study, volunteers will attend regular clinic visits over about 12 weeks. At each visit, doctors will check how the disease is doing using a scoring system called the Modified Mayo Score, which looks at symptoms, a visual exam of the colon (called an endoscopic exam), and lab results. A “clinical remission” means the person’s symptoms have become minimal or disappeared, while a “clinical response” means the symptoms have improved but may not be completely gone. An “endoscopic improvement” indicates that the lining of the colon looks better when viewed with a camera, and “histologic” improvement means that tissue samples show less inflammation under a microscope. Safety will be monitored by recording any side effects and noting if anyone stops the treatment because of them.

The purpose of the trial is to find out whether a planned stopping strategy is safer, works better and leads to higher satisfaction compared with continuing the usual maintenance dose of the JAK inhibitor.

Participants who meet the remission criteria will be randomly assigned to either stop the medication (receiving a placebo) or keep taking the same dose for a period of about one year, with optional follow‑up for a second year. During this time they will have regular check‑ups to monitor any return of symptoms, side effects, and overall well‑being, using simple questionnaires and routine examinations.

Two treatment approaches are being compared. One group receives a combination of three drugs after an initial chemotherapy period: a taxane called paclitaxel, an antibody that blocks blood‑vessel growth named ramucirumab, and an immune‑system‑activating antibody called tislelizumab. The other group continues the standard chemotherapy regimen together with tislelizumab. Paclitaxel works by stopping cancer cells from dividing, ramucirumab stops new blood vessels that feed the tumor, and tislelizumab helps the body’s immune cells recognize and attack cancer.

The purpose of the trial is to determine whether the switch to the three‑drug combination can keep the disease from getting worse for a longer time compared with continuing the original chemotherapy. After about three months of initial therapy, participants are randomly assigned to one of the two arms and receive treatment cycles every few weeks. Tumor scans are performed roughly every two months to check for growth, and the time from random assignment until the cancer progresses or the patient dies is recorded as PFS. Safety checks and quality‑of‑life questionnaires are also completed throughout the study.

The purpose of the study is to determine whether this dose of the drug reduces the likelihood of developing pancreatitis after the procedure. Participants receive the infusion shortly before the ERCP, remain in the hospital for observation, and are checked for abdominal pain, blood test results, and any imaging signs of pancreatitis for up to 48 hours, with additional follow‑up for about a month to monitor any complications or side effects.

After the initial monitoring period, participants may have brief clinic visits or phone calls to assess recovery, quality of life, and any additional medical care needed. A small number of participants will also have blood drawn to measure drug levels, helping researchers understand how the medicine behaves in the body.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.

People with the condition will take the test powder by mouth and then provide urine samples a few hours later, while blood and stool samples will also be collected at scheduled visits. These visits will occur at the start of the study, after about six months, and again after twelve months, during which the usual diet advice will continue. The study will compare the test results with standard assessments such as the Marsh-Oberhuber classification that describes the degree of intestinal damage, to determine whether the test reliably reflects changes in the gut over time.

The aim is to see whether the combination improves the lining of the intestine better than the injectable medication alone over a 12‑week period. Participants will receive the assigned medication(s) at regular intervals and will have routine visits where doctors may use a thin camera (a endoscopic exam) to look at the intestine and check for improvement. The study will last about three months, after which the results will be evaluated.

The aim of the trial is to find out whether the mirikizumab approach leads to a higher rate of deep remission after one year. Deep remission means that a person’s symptoms are low enough to score below 150 on the CDAI (a questionnaire that rates Crohn’s disease activity), that the intestinal lining looks normal on a scope with a score of 2 or less on the SES‑CD system, and that no steroids, surgeries, fistulas, or new narrowings have been needed. Participants are followed for about 52 weeks, with regular clinic visits for medication administration, safety checks, and routine assessments of symptoms and gut health.

Participants will receive one of the two medicines while they are under anesthesia for the surgery. After the operation, they will stay in the recovery area and be asked to rate their pain at several times during the first day. Pain will be measured with the Visual Analogue Scale, a simple line where patients mark how strong their pain feels, from “no pain” to “worst pain imaginable.” Researchers will also watch for common side effects such as nausea, itching, or breathing problems.

The follow‑up period lasts about 24 hours, during which the amount of additional pain medication needed and any unwanted reactions will be recorded. At the end of the study, the collected information will help decide if the new medication method can be used as an alternative to the current standard for managing pain after this surgery.

Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.